Janssen China R&D

Today, China is facing a wide array of complex and unmet medical needs: 93 million people with chronic hepatitis B [1], about 173 million people with a mental disorder [2] and 114 million with diabetes [3]. Some 36 percent of new lung cancer patients globally are in China [4] and it is projected that by 2030, COPD will kill 3 million Chinese people a year [5].

As a global leader in human health, Janssen has an important role to play in addressing these significant medical needs and creating value through innovation in R&D and medical scien
[2] University of Melbourne –
[3] Journal of the American Medical Association,
 [4] Wanqing, C. (2014). The epidemiology of lung cancer in China,
 [5] Hughes, V. (2012). Public health: where there’s smoke,